Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

a direct license with Orcrist. BioMS assigned all BioMS owned patents relating to HYC750 and transfered all HYC750 assets to Orcrist. Under the terms of the agreement, BioMS will receive certain milestone payments in addition to a royalty on net sales of products which otherwise would have infringed on patents related to the HYC750 technology.

BioMS also ceased all development activities with respect to BioCyDex. Future development or licensing activities will be the responsibility of BioCyDex.

Financial Results

The consolidated net loss for the year ended December 31, 2008 was $0.5 million or ($0.01) per share compared with a consolidated net loss of $47.2 million or ($0.56) per share for the previous year. The consolidated net income for the three months ended December 31, 2008 was $0.3 million or $0.01 per share compared with a net loss of ($11.7) million or ($0.13) per share for the previous year.

Revenue of $52.6 million was recorded for the year ended December 31, 2008 compared to $Nil for the year ended December 31, 2007. The revenue is the result of the amortization of the upfront payment and development milestone received from the Agreement with Lilly. Investment income earned on funds invested for the year ended December 31, 2008 increased to $2.4 million from $1.6 million for 2007 due to the increase in cash and cash equivalents as a result of the Agreement with Lilly. The increase was partially offset by a general reduction in interest rates experienced in the market. The investment income is earned from the short-term investment of cash reserves in low risk term deposits and bankers acceptance notes.

Total consolidated expenses for the year ended December 31, 2008 were $61.9 million compared with $48.0 million for 2007. Total consolidated expenses for the three months ended December 31, 2008 totaled $16.5 million as compared to $12.1 million in the same quarter the previous year.

Research
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Research and Markets ... PharmaBiotech,s new report "Gene Therapy - Technologies, Markets ... markets for gene therapy are difficult to estimate as ... it is marketed in China ... years 2014-2024. The estimates are based on epidemiology of ...
(Date:9/2/2015)... 2015 Biovista Inc. is glad ... 2015 BeHEARD science challenge, a global competition hosted by ... access to the latest life science innovations and technologies. ... pathway analytics capability to support Steven Laffoon ... study of Niemann-Pick Disease Type A (NPA), a rare ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... ENGLEWOOD, Colo. , Sept. 2, 2015 ... focused on developing treatments for urological and related conditions, ... of its planned private placement convertible note financing, raising ... two prior tranches totaling $3.175 million. ... stated, "Proceeds from this private placement are intended to ...
Breaking Biology Technology:Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3
... Fred Alger Management, Inc. (Alger),a leading asset ... M.D. as Vice President, Senior Analyst/Co-Portfolio Manager for,Alger ... and,pharmaceutical industries., David received his Doctor of ... was Chief Medical Resident. While in Pennsylvania David,served ...
... obsolete? EnviroChip™ white papers show how consumers like you can ... damaging your engine. , ... Denver (PRWEB) July 28, ... that EnviroChip™, a revolutionary fuel harmonizing microchip, can eliminate a consumer,s ...
... University of Pennsylvania have created a one-step, repeatable ... or motifs with adjustable features, size and shape ... took advantage of the elastic instability of a ... When exposed to a solvent, circular pores ...
Cached Biology Technology:David Farhadi, M.D. to Join Alger as Vice President, Senior Analyst/Co-Portfolio Manager 2Penn researchers demonstrate a flexible, 1-step assembly of nanoscale structures 2Penn researchers demonstrate a flexible, 1-step assembly of nanoscale structures 3
(Date:8/18/2015)... Aug. 17, 2015 Research and Markets ... the "Global Biometric Authentication & Identification Market: ... & Forecast, 2015-2020" report to their offering. ... identification systems market is expected to grow at ... 2020 and generate over $25 billion (approximately) by ...
(Date:8/12/2015)... 12, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that four of its fingerprint ID ... officially been named FIDO Certified™ by the Fast ... certification, Synaptics, Natural ID™ fingerprint solutions are fully ... (UAF) standard and are interoperable among other products ...
(Date:8/6/2015)... and TELTOW, Germany , ... 2015 Siggraph Conference, SensoMotoric Instruments (SMI) shows ... reality , based on Epson,s Moverio BT-200 ... tracking platform. With this new solution, unprecedented quality and ... hands-free interaction with context-sensitive displays. For the first time, ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... Sperm whales weigh up to 50 tons, and the smallest ... the same success story: They both have developed the ability ... Now Danish researchers show that the biosonar of toothed ... they live in very different environments and vary extremely in ...
... that glioma is derived from brain tumor stem cells, ... are still unclear. The potential of neural stem cells ... been considered, but has not been confirmed. A team ... Hospital of Nanjing Medical University, China found that doxycycline-induced ...
... active immunization in Alzheimer,s disease can increase the ... but it is easy to induce meningoencephalitis, which ... To enhance anti-Aβ antibody generation and induce a ... from the First Affiliated Hospital of China Medical ...
Cached Biology News:Bats and whales behave in surprisingly similar ways 2Bats and whales behave in surprisingly similar ways 3
... pyruvate, 50 mg/L streptomycin sulfate, 100 mg/L ... and magnesium chloride. The use of a ... is generally attributed to early workers in ... a solution of inorganic salts designed to ...
This free-standing laminar flow hood provides a horizontal flow of HEPA-filtered air to create a clean processing area. Air return slots along the front and side edges of the work area enhance system...
... dramatic breakthrough in accurate, small-volume bulk dispensing. Dispensing ... micro 1 has unique advantages not found in ... never needs re-calibration as do other 1mL dispensers. ... LCD Display , Graphical Row Selection , 96-,384- ...
... The B1 series embodies all aspects ... compact microscope. With powerful Achromatic Super Contrast ... integrated imaging chip, this microscope combines flexibility ... on Motic's popular B1 series, the DM-B1 ...
Biology Products: